Table 5.
Main characteristics and spondyloarthritis features in the 18 patients with enthesitis by power Doppler ultrasonography who did not meet ASAS criteria for axSpA
| Age(DD) in yearsGender | ESSG/ Amor | TotalASAS SpA features | ASAS spondyloarthritis feature | ||||||||||
| IBP | Arthritis | Enthesitis | Uveitis | Dactylitis | Pso | NSAID | CIBD | FH of SpA | HLA-B27 | CRP >6 mg/L | |||
| 32 (1.34)M | +/+ | 4 | + | – | + | – | – | – | + | + | – | – | – |
| 25 (1.08)F | +/+ | 5 | + | + | + | MD | – | MD | + | MD | + | – | – |
| 39 (3.00)F | +/+ | 4 | + | – | + | MD | – | MD | + | MD | + | – | – |
| 35 (2.58)M | +/+ | 6 | + | – | + | + | – | – | + | – | + | – | + |
| 47 (1.61)F | +/+ | 3 | + | MD | + | MD | – | MD | + | MD | – | – | – |
| 32 (2.78)F | +/+ | 3 | + | – | – | – | – | + | + | – | – | – | – |
| 49 (0.88)F | +/+ | 6 | + | + | + | – | – | + | + | – | – | – | + |
| 35 (1.44)M | +/+ | 5 | + | + | – | – | – | + | + | – | – | – | + |
| 48 (1.93)F | +/+ | 5 | + | + | + | MD | – | MD | + | MD | + | – | MD |
| 39 (3.30)F | +/+ | 2 | + | - | + | MD | – | MD | – | MD | – | – | – |
| 28 (1.33)F | +/– | 4 | + | + | + | – | – | + | – | – | – | – | – |
| 44 (1.40)F | +/+ | 4 | + | + | + | MD | – | MD | + | MD | – | – | – |
| 26 (1.62)F | +/– | 3 | + | – | + | – | – | + | – | – | – | – | – |
| 45 (0.44)M | +/MD | 3 | + | – | + | – | – | – | MD | + | – | – | – |
| 42 (2.76)F | +/– | 3 | + | – | + | MD | – | MD | + | MD | – | – | – |
| 48 (1.42)F | +/– | 2 | + | MD | + | MD | – | MD | – | MD | – | – | – |
| 34 (2.38)M | –/– | 3 | + | MD | – | – | – | + | + | – | – | – | – |
| 31 (0.41)M | -/– | 2 | + | MD | – | MD | – | MD | + | MD | – | – | – |
M for male patients and F for female patients.
ASAS, Assessment of SpondyloArthritis international Society; axSpA, axial spondyloarthritis; CIBD, chronic inflammatory bowel disease; CRP, C reactive protein; DD, disease duration, ESSG, European Spondyloarthropathy Study Group; FH, family history; IBP, inflammatory back pain; MD, missing data; NSAID, non-steroidal anti-inflammatory drug; Pso, psoriasis; SpA, spondyloarthritis.